Rebamipide

Rebamipide

Rebamipide is a quinolinone derivative that is used as a mucoprotective agent. It was first developed in Japan by Otsuka Pharmaceutical and is commonly used in several Asian countries, including South Korea and India.

Mechanism of Action

Rebamipide works by enhancing mucosal defense, increasing prostaglandin production, and scavenging free radicals. It also inhibits Helicobacter pylori adhesion to gastric epithelial cells.

Uses

Rebamipide is primarily used for the treatment of gastritis and peptic ulcer disease. It is also used in the treatment of dry eye disease, as it stimulates the production of mucin, a key component of the tear film.

Side Effects

Common side effects of Rebamipide include gastrointestinal disturbances, such as diarrhea and abdominal pain. Rare side effects can include skin rash, itching, and urticaria.

Contraindications

Rebamipide should not be used in patients with known hypersensitivity to the drug. It should also be used with caution in patients with a history of gastrointestinal bleeding.

Interactions

Rebamipide may interact with other drugs like antacids and proton pump inhibitors. Therefore, it is important to inform the healthcare provider about any other medications being taken.

Pharmacokinetics

Rebamipide is well absorbed from the gastrointestinal tract and is metabolized in the liver. It is excreted in the urine.

References

• Rebamipide in the treatment of gastric ulcers and gastritis: a clinical guide. Drug Design, Development and Therapy. 2018.
• Rebamipide: a novel treatment for dry eye syndrome. Clinical Ophthalmology. 2015.